Mold-Tek Packaging delivered a robust Q2 FY27 performance, posting a 36% profit surge and 10.1% volume growth. Growth was powered by high-value segments like Pharma and FMCG, which offset a decline in the lubricant category. The company maintains an EBITDA guidance of INR 45-46 per kg and is focused on scaling specialty closures and pharmaceutical packaging to drive long-term expansion.
Mold-Tek Packaging Q2 Profit Up 36%
Profit grows 36% YoY, volume increases 10.1%.
Reader Takeaway: Strong high-value segment growth boosts margins, though lubricant segment headwinds and project execution timelines remain key variables.
What just happened
Mold-Tek Packaging Limited reported strong Q2 FY27 results, anchored by a 36% year-on-year rise in profits. Total volume grew by 10.1% compared to the same period last year. The company achieved an EBITDA per kg of INR 46.5, surpassing previous benchmarks. Management attributed this improvement to a shift in product mix toward high-value components and efficiency gains from consolidated Hyderabad production facilities.
Segment and Operating Performance
Performance was notably split across the company's core verticals:
- Pharma & FMCG: The standout performers, with volume growth of 26.3% in pharma and 23.7% in food and FMCG.
- Paints: Recorded steady growth of 9%.
- Lubricants: A soft spot, with volume declining 12.3% due to supply-side challenges at major private-sector clients.
Strategic Developments
The company is diversifying beyond its traditional base. Seven specialty closure products were approved by Vibe, with commercial production targeted for early 2027. Additionally, the Iodex project is set to begin commercial production by early 2027. Longer-term, Mold-Tek is exploring the semiconductor tray market and developing auto-injector pens for the pharma sector.
Management Guidance
Management expects to maintain an EBITDA per kg of INR 45-46 for the full fiscal year. Capital expenditure is planned at INR 75-80 crore, with expectations for positive free cash flow generation. The company has reaffirmed its revenue target of INR 50 crore for the pharma segment for FY27.
Risks to watch
Rising freight costs are presenting challenges for export margins. Furthermore, the company's future revenue potential is tethered to the successful regulatory approval and partnership onboarding for new initiatives like auto-injectors and semiconductor components.
What to track next
Investors should monitor the commercial ramp-up of the Iodex project and the progress of the Vibe partnership to see if they can effectively offset the ongoing weakness in the lubricant packaging segment.